FDAsafety guidance72% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Novartis.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Rheumatology · Still's Disease
- Sub-indication
- General
Related signal: Novartis initiates Phase II trial of MAS825 for Still's Disease